Inhibition of HEV Replication by FDA-Approved RdRp Inhibitors.

ABSTRACT: Hepatitis E virus (HEV) is primarily a hepatotropic virus that is responsible for acute hepatitis E in the general population and for chronic hepatitis in immunocompromised individuals. In the absence of a globally accessible vaccine, pegylated interferon-α and ribavirin are the only antiviral agents available for the treatment of chronic patients. As viral RNA-dependent RNA polymerases (RdRps) are indispensable for RNA replication, they are considered potential drug targets. In this study, we screened some well-known RdRp inhibitor molecules, notably, favipiravir, sofosbuvir, remdesivir, filibuvir, and tegobuvir. Of these, monotherapy with favipiravir and sofosbuvir inhibited the RdRp activity with an IC₅₀ value of 10.2 ± 4.9 and 5.2 ± 2.9 μM, respectively, compared to the refe

SUBMITTER: Hooda P 

PROVIDER: S-EPMC10633873 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature